HIGHLIGHTS
- who: Hao Liu from the Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas Microbiology and Immunology, School of Medicine, University of Missouri, Columbia, MO, United States have published the research: Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy, in the Journal: (JOURNAL)
- how: A PD-1/PD-L1 blocking assay was developed to evaluate the blocking efficacy of these dAbs. Next the authors investigated whether CLV3 also block the mouse PD-1/PD-L1 interaction because the authors need to evaluate the antitumor activity of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.